---
company: MAXCYTE, INC.
ticker: MXCT
form: 8-K
filed: 2026-11-10
accepted: 2026-11-10T13:21:10+00:00
accession: 0001104659-26-124829
source: https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/
---

# Maxcyte (MXCT) Q3 2026 earnings

## Header

- Company: Maxcyte, Inc.
- Reported: 2026-11-10 08:21 BMO ET
- Source: 8-K only — accession 0001104659-26-124829, Item 2.02 + Exhibit 99.1
- Verdict: Revenue growth accelerated to 49% YoY in Q3, driven by a large customer instrument purchase and SPL milestones, though operating losses widened.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $10.2M | +49% | — | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.05 | +0.07 | — | Ex. 99.1, income statement |
| Adj. EBITDA | $2,799 | +$1,425 | — | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Instruments | $2.8M | +102.0% | 27% | Driven by accelerated purchase from a large customer |
| PAs and Consumables | $3.1M | +20.0% | 30% | — |
| Licenses | $2.0M | +9.0% | 19% | — |
| Assay Service | $43K | -83.0% | 0% | — |
| Milestones | $1.0M | +295.0% | 10% | Second milestone achieved in 2026 |
| Royalties | $991K | +486.0% | 10% | — |

## Margins and costs

- Gross margin: 83.0% (prior 77.0%, change +6.0 pp)
- Operating expenses: $14.5M (+25.2% YoY)
- One-offs in the quarter: Restructuring expense: $0 (Q3 2025: $3.1M); Impairment of fixed assets: $630K (9M 2026)
- Effective tax rate: 0% (prior-year 0%, year-to-date 0%)
- Non-GAAP bridge: Adds back SPL program related revenue ($1.995M) and inventory reserves ($21K) to GAAP Gross Margin; excludes SPL program related revenue from Gross Margin definition.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---|
| Weighted-average shares outstanding | 103.5M | 106.8M | 106.6M | -3.0M |
| Cash and cash equivalents | $13.4M | $20.1M | — | -$6.7M |
| Short-term investments | $87.9M | $83.0M | — | +$4.9M |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---|
| Full Year 2026 Total Revenue | $132.7M | $132.7M | No change |

## What drove it

- Revenue story: Core revenue grew 27% YoY, led by a 102% jump in Instruments from a large customer and a 295% increase in Milestones; Royalties surged 486%.
- EPS story: GAAP net loss per share improved to -$0.05 from -$0.12 YoY, driven by higher revenue and gross margin expansion.
- One-off check: Restructuring expense of $3.1M in Q3 2025 is a one-time item not recurring in Q3 2026.

## The good

- Core revenue grew 27% YoY
- Gross margin expanded 6.0 pp YoY to 83.0%
- Milestones and Royalties both surged over 400% YoY

## The bad

- Operating loss widened to -$6.0M from -$14.1M YoY
- Assay Service revenue collapsed 83% YoY

## The ugly

- Operating expenses increased 25.2% YoY to $14.5M, outpacing revenue growth
- Cash and cash equivalents declined $6.7M YoY to $13.4M

## Open questions

- What is the specific amount of the guaranteed deferred payments related to the Akron acquisition?
- How will the Akron Bio acquisition impact the company's debt service obligations and cash position?
- What caused the 83% decline in Assay Service revenue?

## Full release

### Maxcyte (MXCT) earnings release, November 10, 2026

Maxcyte, Inc. (MXCT) · Form 8-K, Item 2.02 · Filed 2026-11-10 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/)

MaxCyte Reports

Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance

MaxCyte will host its third quarter 2026 earnings call today, November 10 th, at 8:30 a.m. Eastern Time

Third Quarter and Recent Business

Highlights:

ROCKVILLE,

MD, November 10, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2026 financial results and raised its 2026 total revenue guidance.

"Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value,” said Maher Masoud, President and CEO of MaxCyte. “MaxCyte’s third quarter results reflect the progress that we have made throughout 2026, with approximately 15% year-over-year core revenue growth expected in the second half of this year, exceeding the growth expectations we established at the beginning of 2026. Looking ahead, our SPL partners are at the forefront of cell therapy program development, with more late-stage programs than ever before, including two pivotal trials that could result in approvals as early as next year. Our enterprise pharma partnership is off to a strong start and represents an exciting opportunity to support its advancing cell therapy pipeline. Together, with building adoption in early research, we now have a broad set of solutions at every stage, from discovery through commercialization. We believe we have strong momentum heading into the end of the year and remain committed to executing on our priorities to drive durable long-term growth.”

Third Quarter

Financial Results¹

Full

Year 2026 Guidance

The pro forma amount above is presented solely to provide a comparison, on a consistent basis, to the $132.7 million of total cash, cash equivalents and investments as of September 30, 2026. Because it excludes the cash purchase price, deal-related expenses and other costs related to the Akron acquisition, it is not a forecast of the Company’s actual year-end cash position, and the Company does not expect to hold approximately

$133 million of total cash, cash equivalents and investments as of December 31, 2026.

The following tables provide details regarding the sources of our revenue for the periods presented.²

Webcast and Conference Call Details

MaxCyte will host a conference call today, November 10, 2026, at 8:30 a.m. Eastern Time.

A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.

You can access the conference call by dialing (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S. The conference ID is

1965284.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Learn more at maxcyte.com and follow us on

LinkedIn and

Bluesky.

Non-GAAP Financial

Measures

This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization.

MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The Company's management uses these non-GAAP measures to compare the Company's performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.³

This press release also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability.

Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with

GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company's financial statements. In order to compensate for these limitations, management presents these

Non-GAAP financial measures along with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance... (truncated)lts. Reconciliation tables of net loss, the most comparable

GAAP financial measure, to EBITDA, and Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin, are included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the Company's business.

Forward-Looking

Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities

Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading "Risk Factors" and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, customer expectations and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," "might," "will," "could,"

"would," "should," "expect," "plan," "anticipate," "intend," "believe,"

"estimate," "seek," "predict," "future," "project," "potential," "continue,"

"contemplate," "target," the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, our full year 2026 revenue and cash guidance, expectations regarding core business revenue growth in the second half of 2026, the proposed acquisition of Akron Bio, the benefits of the Akron acquisition, including the revenue base assumptions, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; expectations regarding customer-level activities (including the expected advancement of our SPL partners' clinical programs, including Phase 3 trial initiations); our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.⁴

Risks and uncertainties related to the proposed acquisition of Akron Bio include, but are not limited to, the possibility that various conditions to the consummation of the proposed transaction may not be satisfied or waived; the risk that shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; that the acquisition may not close on the expected timeline or at all; the significant costs of the acquisition, which have reduced our cash resources and increased our fixed obligations, including $20.0 million of guaranteed deferred payments; dilution to our stockholders from issued shares of common stock; our ability to integrate Akron Bio and realize the anticipated benefits of the acquisition; and risks related to our new indebtedness under our credit facility, including our debt service obligations. These and other risks and uncertainties are described in greater detail in Item 1A, entitled "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com.

Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

Erik Abdow ir@maxcyte.com

Media

Contact

Oak Street Communications

Kristen White kristen@oakstreetcommunications.com

415.608.6060⁵

MaxCyte, Inc.

Unaudited Condensed

Consolidated Balance Sheets

(in thousands, except share and per share amounts)⁶

MaxCyte, Inc.

Unaudited Condensed

Consolidated Statements of Operations

(in thousands, except share and per share amounts)⁷

MaxCyte, Inc.

Unaudited Condensed

Consolidated Statements of Cash Flows

(in thousands)⁸

Unaudited Reconciliation of Net Loss to EBITDA

(in thousands)

(Unaudited)⁹... (truncated)liation of Gross Margin to Non-GAAP Adjusted Gross Margin

(in thousands, except for percentages)

(Unaudited)¹⁰

#### Financial statements

##### Income Statement (Three Months Ended — The following tables provide details regarding the sources of our revenue for the periods presented. (in thousands, except percentages))

| | Three Months Ended – September 30 (Unaudited) – 2026 | Three Months Ended – September 30 (Unaudited) – 2025 | % |
|---|---:|---:|---:|
| Instruments | 2,779 | 1,376 | 102.0% |
| PAs and Consumables | 3,092 | 2,577 | 20.0% |
| Licenses | 1,967 | 1,803 | 9.0% |
| Assay Service | 43 | 248 | -83.0% |
| Other | 276 | 402 | -31.0% |
| Total Core Revenue | 8,157 | 6,406 | 27.0% |
| Milestones | 1,004 | 254 | 295.0% |
| Royalties | 991 | 169 | 486.0% |
| Total Revenue | 10,152 | 6,829 | 49.0% |

##### Income Statement (Three Months Ended September 30, — (in thousands, except share and per share amounts))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 10,152 | 6,829 | 27,074 | 25,726 |
| Cost of goods sold | 1,684 | 1,596 | 4,928 | 4,612 |
| Gross profit | 8,468 | 5,233 | 22,146 | 21,114 |
| **Operating expenses:** | | | | |
| Research and development | 2,874 | 5,316 | 10,984 | 17,488 |
| Sales and marketing | 4,214 | 3,936 | 11,006 | 15,420 |
| General and administrative | 6,553 | 6,028 | 19,777 | 22,634 |
| Restructuring expense |  | 3,058 |  | 3,058 |
| Depreciation and amortization | 868 | 1,044 | 2,837 | 3,185 |
| Total operating expenses | 14,509 | 19,382 | 44,604 | 61,785 |
| Operating loss | -6,041 | -14,149 | -22,458 | -40,671 |
| **Other income:** | | | | |
| Interest income | 1,279 | 1,733 | 4,072 | 5,637 |
| Total other income | 1,279 | 1,733 | 4,072 | 5,637 |
| Loss before income taxes | -4,762 | -12,416 | -18,386 | -35,034 |
| Net loss | -4,762 | -12,416 | -18,386 | -35,034 |
| Comprehensive loss | -4,762 | -12,416 | -18,386 | -35,034 |
| Basic and diluted net loss per share | -0.05 | -0.12 | -0.17 | -0.33 |
| Weighted-average shares outstanding, basic and diluted | 103,537,926 | 106,613,075 | 105,732,991 | 106,324,792 |

##### Income Statement (Three months ended September 30, 2026 — (Unaudited) (in thousands))

| | Three months ended September 30, 2026 – GAAP | Three months ended September 30, 2026 – Adjustments | Three months ended September 30, 2026 – Non-GAAP | Three months ended September 30, 2025 – GAAP | Three months ended September 30, 2025 – Adjustments | Three months ended September 30, 2025 – Non-GAAP |
|---|---:|---:|---:|---:|---:|---:|
| Revenue | 10,152 | -1,995 | 8,157 | 6,829 | -423 | 6,406 |
| Cost of Goods Sold | 1,684 | -21 | 1,663 | 1,596 | -360 | 1,236 |
| Gross Margin | 8,468 | -1,974 | 6,494 | 5,233 | -63 | 5,170 |
| Gross Margin % | 83.0% |  | 80.0% | 77.0% |  | 81.0% |

##### Income Statement (Nine months ended September 30, 2026 — (Unaudited))

| | Nine months ended September 30, 2026 – GAAP | Nine months ended September 30, 2026 – Adjustments | Nine months ended September 30, 2026 – Non-GAAP | Nine months ended September 30, 2025 – GAAP | Nine months ended September 30, 2025 – Adjustments | Nine months ended September 30, 2025 – Non-GAAP |
|---|---:|---:|---:|---:|---:|---:|
| Revenue | 27,074 | -6,197 | 20,877 | 25,726 | -2,878 | 22,848 |
| Cost of Goods Sold | 4,928 | -400 | 4,528 | 4,612 | -525 | 4,087 |
| Gross Margin | 22,146 | -5,797 | 16,349 | 21,114 | -2,353 | 18,761 |
| Gross Margin % | 82.0% |  | 78.0% | 82.0% |  | 82.0% |

##### Balance Sheet (September 30, — (in thousands, except share and per share amounts))

| | September 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| **Current assets:** | | |
| Cash and cash equivalents | 13,372 | 20,065 |
| Short-term investments, at amortized cost | 87,908 | 82,979 |
| Accounts receivable, net | 12,054 | 3,503 |
| Inventory, net | 7,380 | 7,547 |
| Prepaid expenses and other current assets | 3,777 | 4,275 |
| Assets held for sale | 180 |  |
| Total current assets | 124,671 | 118,369 |
| Investments, non-current, at amortized cost | 31,469 | 52,570 |
| Property and equipment, net | 14,342 | 17,531 |
| Right-of-use asset - operating leases | 10,237 | 10,920 |
| Intangible assets, net | 749 | 650 |
| Other assets | 1,015 | 2,467 |
| Total assets | 182,483 | 202,507 |
| **Current liabilities:** | | |
| Accounts payable | 1,026 | 1,401 |
| Accrued expenses and other | 5,937 | 7,812 |
| Operating lease liability, current | 1,565 | 1,456 |
| Deferred revenue, current portion | 7,388 | 3,598 |
| Total current liabilities | 15,916 | 14,267 |
| Operating lease liability, net of current portion | 15,325 | 16,487 |
| Other liabilities | 311 | 263 |
| Total liabilities | 31,552 | 31,017 |
| **Stockholders’ equity:** | | |
| Common stock, $0.01 par value; 400,000,000 shares authorized, 107,493,772 and 106,789,618 shares issued, and 103,233,238 and 106,789,618 outstanding at September 30, 2026 and December 31, 2025, respectively | 1,075 | 1,068 |
| Additional paid-in capital | 435,225 | 431,905 |
| Treasury stock, 4,260,534 shares, at cost | -5,500 |  |
| Accumulated deficit | -279,869 | -261,483 |
| Total stockholders’ equity | 150,931 | 171,490 |
| Total liabilities and stockholders’ equity | 182,483 | 202,507 |

##### Cash Flow (Nine Months Ended September 30, — (in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities:** | | |
| Net loss | -18,386 | -35,034 |
| **Adjustments to reconcile net loss to net cash used in operating activities:** | | |
| Depreciation and amortization | 2,925 | 3,268 |
| Impairment of fixed assets | 630 |  |
